DISOPYRAMIDE
(Rythmodan)Standard Prescription
disopyramide__mg PO Q__H (__mg/kg/24hr)
Dosages
Children:
< 1 yr old: 2.5-7.5 mg/kg/dose PO QID
1-4 yr old: 2.5-5 mg/kg/dose PO QID
4-12 yr old: 2.5-4 mg/kg/dose PO QID
12-18 yr old: 1.5-4 mg/kg/dose PO QID
Adults:
< 50 kg: 100 mg PO Q6H
> 50 kg: 150 mg PO Q6H
If no response, may increase dose to 200 mg PO Q6H (adults)
< 1 yr old: 2.5-7.5 mg/kg/dose PO QID
1-4 yr old: 2.5-5 mg/kg/dose PO QID
4-12 yr old: 2.5-4 mg/kg/dose PO QID
12-18 yr old: 1.5-4 mg/kg/dose PO QID
Adults:
< 50 kg: 100 mg PO Q6H
> 50 kg: 150 mg PO Q6H
If no response, may increase dose to 200 mg PO Q6H (adults)
Mechanism of Action
Class Ia antiarrhythmic, prolongs QRS and QT durations.
targets sodium channels to inhibit conduction.
Forms Supplied
capsule: 100 mg
oral suspension (BCCH): 1 mg/mL, 5 mg/mL, 10 mg/mL
oral suspension (BCCH): 1 mg/mL, 5 mg/mL, 10 mg/mL
Comments
Occasionally used for obstructive cardiomyopathy.
Negative inotropic effects.
Some anticholinergic side effects may occur (dry mouth, urinary hesitancy).
Decrease dose in renal failure
Interacts with erythromycin, clarithromycin, antifungals to increase levels of disopyramide resulting in increased risk of cardiotoxicity (major cytochrome P450 substrate)
Negative inotropic effects.
Some anticholinergic side effects may occur (dry mouth, urinary hesitancy).
Decrease dose in renal failure
Interacts with erythromycin, clarithromycin, antifungals to increase levels of disopyramide resulting in increased risk of cardiotoxicity (major cytochrome P450 substrate)
References
44, 192
Last Edited
2019-01-22 17:59:20